Placing of New Ordinary Shares

14 April 2010

                             Scancell Holdings Plc                             

                                (the "Company")                                

                        Placing of New Ordinary Shares                         

Scancell Holdings Plc, (PLUS:SCLP), the developer of therapeutic cancer
vaccines, is pleased to announce it has raised £207,000 (before expenses) by
way of a placing of 460,000 New Ordinary Shares of 0.1p each (`Placing Shares')
at a price of 45p (the `Placing') with the Aspire Fund. The net proceeds of the
Placing, together with the proceeds of the Open Offer that was completed on 29
March 2010, will be used to fund the working capital requirements of the
Company to take its lead melanoma vaccine, SC1B1, through Phase I and Phase IIa
Clinical Trials.

Admission and commencement of dealings in the New Ordinary Shares to be issued
under the Placing are expected to take place at 8.00 a.m. on 15 April 2010.
There will be a total of 15,873,326 Ordinary Shares in issue following
Admission of the Placing Shares.

David Evans, Chairman of Scancell Holdings plc, commented:

"Following the recent successful fundraising, I am delighted that the Aspire
Fund has now also decided to become a significant shareholder in Scancell. The
investment represents further recognition of the work of our CEO Lindy Durrant
in the development of SC1B1."

Melanie Perkins, Lead Manager of the Aspire Fund said:

"This investment is extremely exciting and we are thrilled to have the
opportunity to support such a vital enterprise that may have the opportunity to
save so many lives. The Aspire Fund seeks to support and encourage female
entrepreneurship and Scancell is an excellent example of women leading the way
in diverse and important fields of work."

The Directors of the issuer accept responsibility for this announcement.

                                    -ENDS-                                     

For Further Information:

David Evans, Chairman           Scancell Holdings Plc    + 44 774 008 4452   
                                                                             
Professor Lindy Durrant, CEO    Scancell Holdings Plc    + 44 207 245 1100   
                                                                             
Kirsty Corcoran/John Bick       Hansard Communications   + 44 207 245 1100   
                                                                             
Ross Andrews / Tom Rowley       Zeus Capital             + 44 161 831 1512   

About the Aspire Fund (www.capitalforenterprise.gov.uk)

Established in November 2008, the £12.5m Aspire Fund targets support for
women-led businesses with an objective to increase the number of successful
female entrepreneurs within the UK, ensuring that those with real potential to
succeed are not held back through a lack of growth capital. The Fund is able to
make investments of between £100k and £1m, providing up to 50% of capital in a
funding round alongside other private investors. The Aspire Fund is managed by
Capital for Enterprise Ltd (CfEL) on behalf of the Department for Business
Innovation and Skills (BIS).

About Scancell

Scancell is developing novel therapeutic vaccines for the treatment of cancer
and infectious diseases based on its groundbreaking ImmunoBody® technology
platform. Scancell's first cancer vaccine SCIB1 is being developed for the
treatment of melanoma and is expected to enter clinical trials in 2010.

Treating cancer by vaccination allows small non-toxic doses of a vaccine to be
administered to a patient, stimulating an immune response. Effective cancer
vaccines need to target dendritic cells to stimulate both parts of the cellular
immune system; the helper cell system where inflammation is stimulated at the
tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system
cells are primed to recognise and kill specific cells.

A limitation of many cancer vaccines currently in development is that they
cannot specifically target dendritic cells in vivo. Several groups have
demonstrated successful vaccination by growing dendritic cells ex vivo, pulsing
them with tumour antigens and re-infusing them. However, this procedure is
patient specific, time consuming and expensive. Scancell has developed its
breakthrough patent protected ImmunoBody® technology to overcome these
limitations.

An ImmunoBody® is a human antibody or fusion protein engineered to express
helper cell and CTL epitopes from tumour antigens over-expressed by cancer
cells. Antibodies are ideal vectors for carrying T cell epitopes from tumour
antigens as they have long half-lives and can effectively target dendritic
cells via their Fc receptors, allowing efficient stimulation of both helper and
CTL responses.

The Immunobody® technology can be adapted to provide the basis for treating any
tumour type and may also be of potential utility in the development of vaccines
against hepatitis, HIV and other chronic infectious diseases.